Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 257

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 257
---
 Hansoh Agreement for the three months ended June 30, 2025, compared to $37.0 thousand for the three months ended June 30, 2024. The increase in total revenue of $18.1 million was due to the Takeda Agreement.

Research and Development Expenses 

The following table summarizes our research and development expenses for the three months ended June 30, 2025 and 2024 (in thousands): 

THREE MONTHS ENDED JUNE 30,INCREASE / (DECREASE)20252024KER-0651,431 2,926 (1,495)Elritercept15,636 11,001 4,635 Cibotercept4,059 6,731 (2,672)Preclinical and development fees1,981 2,733 (752)Personnel expenses (including stock-based compensation)15,683 13,783 1,900 Professional fees1,736 1,099 637 Facilities and supplies2,452 1,578 874 Other expenses525 664 (139)$43,503 $40,515 $2,988 

Research and development expenses were $43.5 million for the three months ended June 30, 2025, compared to $40.5 million for the three months ended June 30, 2024. The increase of $3.0 million was primarily due to (i) an increase of $4.6 million of elritercept-related expenses, primarily driven by an increase of $4.3 million in clinical spend associated with our ongoing Phase 2 clinical trials, one in patients with MDS and one in patients with myelofibrosis, and the advancement of a 

26

Phase 3 clinical trial in patients with MDS, and an increase of $0.3 million in manufacturing activities; (ii) an increase of $1.9 million related to personnel expenses, including an increase of $0.3 million of additional stock-based compensation costs, driven by increased severance costs; and (iii) a net increase of $1.4 million in facilities, supplies, professional fees and other expenses. These increases were partially offset by (a) a decrease of $1.5 million of KER-065-related expenses, primarily driven by a decrease of $0.9 million in clinical spend associated with our Phase 1 clinical trial and a net decrease of $0.6